Search

The article presents information on the recent developments related to Alzheimer's disease. Neurologix Inc. has licensed a promising new gene for the treatment of Alzheimer's and other central nervous system disorders from Keio University in Tokyo, Japan as part of a strategic move to broaden its product portfolio. The U.S. National Institute on Aging has awarded $9 million to the University of California, Irvine to support research into Alzheimer's disease and to help fund the development of pioneering treatments. New Jersey-headquartered Ortho-McNeil Neurologics Inc. has launched Razadyne ER, a new once-daily treatment for the symptoms of mild to moderate Alzheimer's disease, in the U.S.

The article reports on the results of several studies related to neurology conducted in 2008. A study on multiple sclerosis found that high-dose interferon beta-1b had little advantage compared to its low-dose version. A study on chronic neuropathic pain suggested a link between pain and rewiring of the brain. A study revealed that the brains of obstructive sleep apnea patients undergo significant changes in white matter.

An introduction is presented in which the editor discusses various reports within the issue on the status and prospects for neurological disorders treatment including dementia, sleep apnoea, and chronic pain.